Novartis AG (NVS)
NYSE • Healthcare
May 22, 2026 at 16:00 UTC
About Novartis AG
Novartis AG is a pharmaceutical company that discovers, develops, and supplies medicines for conditions managed in specialty and primary care. Its model connects research with manufacturing and patient access so new therapies move from trials to practice under consistent standards. Programs focus on areas where evidence, careful dosing, and long follow-up matter, which is why labeling clarity and clinician education sit alongside science as core work. Supply chains and quality systems are organized for continuity rather than spectacle, keeping availability steady once treatment becomes part of care. Country teams adapt to local frameworks while holding to shared safety principles. Within the healthcare sector, Novartis acts as a long-horizon manufacturer and science organization, turning complex research into options that clinicians can use predictably in hospitals and clinics around the world.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Novartis AG's Technical Indicators Summary
NVS shows a constructive technical profile as price sits around the pivot and above the majority of short- and medium-term moving averages while remaining well above the 200‑day average, and on‑balance volume supports the advance. Momentum indicators are mixed but lean positive, and volatility is muted, reflecting orderly gains rather than a spike in risk. Trend strength is modest, so the rally lacks firm directional conviction even as shorter-term trend measures favor buyers. Technical takeaway: Bullish—short/medium moving averages and rising OBV favor the upside, but trend strength is moderate.
| Indicator | Value |
|---|---|
RSI (14) | 54.27 |
Stochastic %K (14, 3, 3) | 83.66 |
CCI (20) | 136.77 |
WPR (14) | -17.92 |
Momentum (10) | 2.09 |
MFI | 54.92 |
MACD Level (12, 26) | -0.13 |
Bollinger Bands | $142.63 - $151.46 |
ATR (14) | $2.50 (1.66%) |
ADX (14) | 12.70 |
OBV | 17,723,812 |
Classic Pivot Point | $150.39 |
Fibonacci Pivot Point | $150.39 |
Simple Moving Averages | $139.59 - $151.31(5 indicators) |
Exponential Moving Averages | $138.69 - $149.63(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
A little upside push leaves NVS 0.24% above yesterday’s close (151.76), recent prints near 152.12. Options flow tilts bullish, with a put/call ratio of 0.70 favoring upside exposure. A mild sector advance (1.28%) slightly supports the backdrop for NVS.
Price Change
from $152.05 close
$0
Trading Volume
Below avg (1.2M)
980.6K
vs S&P 500 Today
Moderate Underperformance
-0.24%
52-Week Position
Upper range
69.1%
Updated: May 22, 2026 at 19:03 UTC
Quote Summary
NVS Headlines
Azoria ETFs shut, Novartis India stake sold, tariff shock
February 20, 2026
Live Nation, PTC, AES Lead Busy Earnings and Energy News
February 19, 2026
Avidity sets spin-off record date pre‑Novartis deal
February 3, 2026
How Recent Rallies Stack Up Against Valuations
January 11, 2026